Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 344 | 64 | 269 |
| Samples | 324 | 61 | 256 |
| Peptides | 267 | 41 | 221 |
Function
MCM6 · Minichromosome maintenance complex component 6
The protein encoded by this gene is one of the highly conserved mini-chromosome maintenance proteins (MCM) that are essential for the initiation of eukaryotic genome replication. The hexameric protein complex formed by the MCM proteins is a key component of the pre-replication complex (pre_RC) and may be involved in the formation of replication forks and in the recruitment of other DNA replication related proteins. The MCM complex consisting of this protein and MCM2, 4 and 7 proteins possesses DNA helicase activity, and may act as a DNA unwinding enzyme. The phosphorylation of the complex by CDC2 kinase reduces the helicase activity, suggesting a role in the regulation of DNA replication. Single nucleotide polymorphisms in the intron regions of this gene are associated with differential transcriptional activation of the promoter of the neighboring lactase gene and, thereby, influence lactose intolerance in early adulthood. [provided by RefSeq, May 2012].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000264156 | Q14566 | 344 | 267 |
Gene Properties
Recurrent Mutations
All 267 amino-acid changes on canonical ENST00000264156 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in MCM6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in MCM6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 4/40 10% | 0/0 0% |
| Endometrial Carcinoma | 5/42 12% | 14/612 2% |
| Non-Small Cell Lung Carcinoma | 17/304 6% | 23/1390 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Melanoma | 4/210 2% | 38/1899 2% |
| Burkitts Lymphoma | 0/32 0% | 3/196 2% |
| Colorectal Carcinoma | 7/143 5% | 34/3239 1% |
| Other Solid Cancers | 3/94 3% | 15/1515 1% |
| Neuroendocrine Tumour | 3/154 2% | 4/577 1% |
| Gastric Carcinoma | 2/74 3% | 16/1809 1% |
| Bladder Carcinoma | 1/58 2% | 8/956 1% |
| Hodgkins Lymphoma | 1/16 6% | 0/122 0% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Hepatocellular Carcinoma | 0/46 0% | 15/2210 1% |
| Esophageal Carcinoma | 1/23 4% | 4/769 1% |
| Ewings Sarcoma | 1/63 2% | 1/262 0% |
| Squamous Cell Lung Carcinoma | 0/57 0% | 5/810 1% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Glioma | 0/52 0% | 11/2127 1% |
| Head and Neck Carcinoma | 0/85 0% | 8/1574 1% |
| Ovarian Carcinoma | 2/109 2% | 3/998 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 11/2550 0% |
| Biliary Tract Carcinoma | 1/54 2% | 3/950 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Other Sarcomas | 1/69 1% | 2/699 0% |
| Breast Carcinoma | 2/144 1% | 9/3264 0% |
| Kidney Carcinoma | 1/85 1% | 5/1862 0% |
| Thyroid Gland Carcinoma | 1/45 2% | 4/1592 0% |
| Pancreatic Carcinoma | 0/89 0% | 5/1611 0% |
| Neuroblastoma | 2/87 2% | 2/1331 0% |
Mutation Distribution
Where MCM6 is mutated · all tissues, split by cell line vs tissue
How many mutations in MCM6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 344 mutations in MCM6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|